^
Association details:
| Biomarker: | KRAS G12D |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | QTX3046 (KRAS G12D inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
LB321 / 12 - Discovery and characterization of QTX3046, a potent, selective, and orally bioavailable non-covalent KRASG12D inhibitor
Published date:
03/15/2023
Excerpt:
In a KRASG12D-driven xenograft model, oral administration of QTX3046 twice daily (BID) achieved tumor regression in 100% of tumors and was well-tolerated….The current PK profile and preclinical proof-of-concept data support advancement of QTX3046 into IND enabling studies to support potential clinical investigation in KRASG12D-driven solid tumor indications.
